INTRODUCTION
• Autosomal dominant polycystic kidney disease (ADPKD) is the most common type of polycystic kidney disease (PKD) and is caused by mutations in at least two known genes, PKD-1 and PKD-2. It is the fourth leading cause of end-stage renal disease (ESRD).
• Medical resource utilisation (MRU) and costs by chronic kidney disease (CKD) stage in ADPKD are not well quantified. In particular, MRU related to ADPKD prior to ESRD are largely unknown.
• The costs associated with medical care of ADPKD patients become substantial in later stages of the disease, which include costs related to dialysis and kidney transplantation. However, there is little available information on MRU in patients with ADPKD in Europe.
OBJECTIVES
• The primary objective of this study was to characterise MRU among ADPKD subjects across all disease stages in routine clinical practice in France, Germany, the UK, Sweden, Spain, and Italy.
• Secondary objectives included describing demographic characteristics (such as gender, age, race, and employment status) and clinical characteristics (such as ADPKD-related complications).
METHODS
• This study was a retrospective review of medical charts collected via an online physician survey. The physicians were recruited from France (n=67), Germany (n=70), the UK (n=67), Sweden (n=15), Spain (n=67), and Italy (n=67).
• Participating physicians abstracted data from the medical charts of the last three eligible ADPKD patients treated in their practice, each within a different CKD stage.
• Subjects were analysed by disease stage, with disease stage subgroups defined by the National Kidney Foundation guidelines for CKD stages. In addition two other subgroups were also defined (ESRD Dialysis and ESRD Post-transplant).
• Data collected included socio-demographics, clinical characteristics and MRU over the past 2 years, such as diagnostic tests, specialist visits, dialysis modality, emergency department visits, inpatient admissions and medications.
• The data analyses were largely descriptive. Pair-wise comparisons of the annual mean number of MRU units were performed between adjacent disease stages. P values were evaluated using a t-test. Descriptive summary statistics for categorical variables included frequency counts and percentages (n [%]).
RESULTS

Sample
• A total of 1,055 ADPKD subjects were enrolled in the study by 353 physicians.
• On average (SD), the participating physicians had been practicing for 17.6 (7.8) years and personally treated an average (SD) of 37.8 (49.3) ADPKD patients.
• The mean (SD) age of the patient sample was 50.4 (14.44) years, 53.6% were male. Age generally increased with advancing disease stages. The sample population was comparable to published ADPKD studies. (Table 1) • The majority (55.4%) of subjects in the overall sample were employed, and most (416 [71.2%] of the 584 employed subjects) were employed full time. Employment rates declined with advancing disease stage, and increasing age within each stage, with the lowest employment rates observed in subjects on dialysis. ( 
Clinical Characteristics
• Only 40% of subjects had a known PKD genotype, of which 83% had PKD-1 and 17% had PKD-2.
• Almost all subjects (99.1%) experienced at least 1 ADPKD-related complication, most commonly hypertension (75.4%). Haematuria (46.1%), proteinuria (36.8%), non-renal cysts (31.6%), upper UTI (23.1%), and nephrolithiasis (8.4%) appeared to be constant over the disease course. Anaemia was more prevalent in subjects in Stage 5 (48.5%) and ESRD Dialysis 
Medical Resource Utilisation
• Specialist visits play an important role in the care of ADPKD patients, with more than threequarters (84.2%) of subjects in the sample having at least 1 nephrologist visit during the 24-month study period. On average (SD), subjects had 4.4 (9.25) annual specialist visits.
• In general, subjects in more advanced disease stages reported higher mean (SD) annual outpatient visits and more disease-related hospitalisations. (Figures 3 and 4 ) • During the study period, 14.6% of subjects visited the emergency department (ED), with most reporting only a single visit. No statistically significant differences were observed between adjacent CKD stages for the annual mean number of ED visits. • Admissions to the ICU accounted for 16.4% of all hospitalisations with a mean (SD) LOS of 0.5 (3.77) days.
• Among those who received regular dialysis during the study period, haemodialysis was most common with 216 subjects (94.7%) in the ESRD Dialysis subgroup recieveing treatment. Only 14 subjects (6.1%) in the ESRD Dialysis subgroup received peritoneal dialysis.
• Almost one-third (31.7%) of the hospitalisations that occurred among subjects in the ESRD Dialysis group included care related to dialysis, while 11.9% of these hospitalisations included preparatory care for dialysis. A wide range of other reasons for hospitalisation were listed for dialysis patients, including hypertension and other cardiovascular reasons, nephritis, haematuria, diabetes, and other ADPKD-and CKD-related reasons.
• Given the high prevalence of hypertension, the majority of subjects were prescribed medications for hypertension. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) were the most commonly prescribed medications, regardless of disease stage. A high prevalence of opioid use in ESRD Dialysis subjects (10%) was observed, reflecting a substantial pain burden due to ESRD. (Table 3) 
CONCLUSIONS
• This is the first study that provides evidence on MRU in ADPKD patients across Europe. This survey provided a comprehensive geographic coverage of nephrologists across different countries in the EU. The size of the study sample and the demographic and clinical characteristics of the survey population were comparable to published ADPKD studies and thus provides evidence representative of the ADPKD population.
• Results of this chart survey demonstrate a high level of MRU associated with ADPKD patients in Europe, particularly those with more advanced disease. Rates of MRU increased at a slower rate from CKD Stages 1 to 4 and at a higher rate between CKD Stage 5 and ESRD/Dialysis.
• Primary care providers were not included in this survey, thus information on primary care was not captured, which may underestimate MRU in this population.
• These findings support the importance of new ADPKD therapies that can slow disease progression and reduce the costs associated with disease-related care, including dialysis, hospitalisation, and specialist care. 
